Adalimumab Biosimilar Yuflyma Gets Approval for Additional Pediatric Indications
The FDA has expanded the approval of Yuflyma (adalimumab-aaty) to include the treatment of hidradenitis suppurativa (HS) in patients aged 12 years and older and uveitis (UV) in pediatric patients aged 2 years and older.
Yuflyma is a tumor necrosis factor (TNF) blocker approved as a citrate-free, high-concentration, interchangeable biosimilar to Humira (adalimumab).
- Supplied as a prefilled syringe in 20mg/0.2mL, 40mg/0.4mL and 80mg/0.8mL dosage strengths
- Also available as an autoinjector in 40mg/0.4mL and 80mg/0.8mL dosage strengths
- Stable at room temperature for up to 31 days
Author's summary: Yuflyma gets FDA approval for pediatric indications.
More News
- Sweden’s still ahead in the preparedness game — and now it means business
- Flyers send Jett Luchanko back to juniors as development takes priority | NorthPennNow
- Hugo Rodrigues: A nine-member Cornwall city council? That's disappointing
- Comment | A spate of dealer anniversaries offers hope amid art market doomerism
- MyForest Foods’ mycelium bacon sizzles as alt meat market cools
- Islamic Heritage Month event in Cornwall showcases how to build community
- Time for Action: Investing in Health Canada to Accelerate Access to…
- Zorin OS Breaks Download Record as Windows 10 Users Seek Alternatives
- SJHN Daily: Celebrini Named NHL First Star of the Week
- Thunderstorms with damaging winds and penny-sized hail in Central West Florida Monday – wind gusts up to 60 mph